Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evinacumab in Persistent Hypercholesterolemia
NCT03175367Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2017
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 20
01
Overview
Phase 2, randomised, double-blind trial of evinacumab in hypercholesterolemia (7 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at 16 weeks. Started Nov 2017; status: completed.
02
Drugs
evinacumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT03175367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03175367.